FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVIB APPRO	JVAL
OMB Number:	3235-0287
Estimated average bu	urden
hours per response	0.4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Duint on True	Dasmanasa)															
(Print or Type Responses) 1. Name and Address of Reporting Person * VERONNEAU MARCEL					2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) 614 MCKINLEY PLACE N.E.						of Ear 2015		ınsact	ion (Month/I	Day/Year)		X_Officer (give title below) Other (specify below) SVP - Clinical Controls				
(Street) MINNEAPOLIS, MN 55413					4. If Amendment, Date Original Filed(Month/Day/Year) 08/11/2015							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
(Instr. 3) Date			2. Transaction Date (Month/Day/Yea				3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Amount (A) or (D) Price		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	enort on a ser	narate line for	r each cla	ass of securities b	eneficially	owi	ned direc	tly or	indirectly							
	oport on a sep	variate fille 101	e cucii cia	ass of securities o		OWI	incu direc	vily of	Persor this fo	ns who respo rm are not red tly valid OMB	quired to re	spond u				1474 (9-02)
				Table I						osed of, or Ben onvertible secu		ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transacti Date (Month/Day	//Year)	3A. Deemed Execution Date, i any (Month/Day/Year	4. Transaction Code		5. Number		T .	rcisable and Date	7. Title and of Underlyi Securities (Instr. 3 and	ng	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 108.49	08/07/2015			A		5,625		(1)	08/07/2022	Common Stock	5,625	\$ 0	5,625	D	
Restricted Stock Units	(2)	08/07/2015		A		900		(1)	(1)	Common Stock	900	\$ 0	900	D		
Report	ing Ow	vners														
P (0 N (41)				Relationships												
Reporting Owner Name / Address Director VERONNEALI MARCEL			or 10% Owner	Officer			Other									

Signatures

614 MCKINLEY PLACE N.E.

MINNEAPOLIS, MN 55413

/s/ Elizabeth M. Dunshee as Attorney-in-Fact for Marcel Veronneau pursuant to Power of Attorney previously filed.	08/20/2015
**Signature of Reporting Person	Date

SVP - Clinical Controls

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.

(2) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

Remarks:

This amendment is being filed solely to correct the number of options and restricted stock units granted on August 7, 2015 as initially reported on August 11, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.